Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.68 |
| ▸ | FNTA | P49354 | 4/20 | 0.60 |
| ▸ | FNTB | P49356 | 4/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.60 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136379 | 1.00 | NOD1 (0.68) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL17204611 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL11418536 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL5664925 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL25188855 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL25264982 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL4741209 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL542916 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL4741211 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 | |
| SCHEMBL11426235 | 0.98 | NOD1 (0.70) | NOD1FNTAFNTBPGGT1BSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101367859-B | Fatty acid bile acid couplet and medical uses thereof | INST PHARM & TOXICOLOGY AMMS | 2011-05-11 | — | — | CN | claimed |
| CN-101367859-A | Fatty acid bile acid couplet and medical uses thereof | POISON MED INST PLA MED ACAD (CN) | 2009-02-18 | — | — | CN | claimed |
| EP-0946499-B1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-06-01 | — | — | EP | claimed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | disclosed |
| CN-101367859-B | Fatty acid bile acid couplet and medical uses thereof | INST PHARM & TOXICOLOGY AMMS | 2011-05-11 | — | — | CN | disclosed |
| CN-101367859-A | Fatty acid bile acid couplet and medical uses thereof | POISON MED INST PLA MED ACAD (CN) | 2009-02-18 | — | — | CN | disclosed |
| EP-0946499-B1 | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-4442090-A | ACYLATED AMINO ACID | KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1984-04-10 | — | — | US | disclosed |
| US-4241085-A | N-ACYL-METHIONINE | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-12-23 | — | — | US | disclosed |
| US-4093740-A | N-ACYL-METHIONINE | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSIER (DT) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | NOD1 3434/4885FNTA 1292/4885FNTB 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.